,169 As an antagonist of IAP, birinapant inhibits IAP to sensitize tumor cells to CAR-T cell-derived TNF and significantly enhances the anti-tumor activity of CAR-T lymphocyte therapy in vitro and in vivo. This evidence concerns the gene TNF and neoplasm.